PTPRC and glioblastoma: The remaining two immunophenotypes, CD45 on CD33br HLA DR+ CD14dim (OR = 1.334, 95% CI = 1.089-1.634, p = 0.005, FDR = 0.027) and CD86 on CD62L+ myeloid DC (OR = 1.307, 95% CI = 1.064-1.606, p = 0.011, FDR = 0.048), were associated with an increased risk of GBM.